Compare General Motors Company (GM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs TG Therapeutics Inc — how do they compare? General Motors Company trades at $76.89 (market cap $70.01B), while TG Therapeutics Inc trades at $54.99 (market cap $8.64B). The key difference: General Motors Company is far larger — about 8.1× TG Therapeutics Inc's market cap, and General Motors Company pays a 0.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GM | TGTX | |
|---|---|---|
Market Cap | $70.01B | $8.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $59.06 |
52-Week Low | $48.89 | $26.39 |
Enterprise Value | $173.34B | $8.88B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.78, down 0.12% on the day, with a neutral technical signal and strong analyst support (63% buy ratings). Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $3.70 surpassing the $2.61 estimate. Revenue for 2025 was $185.02B, though net income margin narrowed to 1.38%. The company maintains solid cash flow from operations of $26.87B in 2025 and recently announced a $0.18 dividend for H1 2026.
GM presents a value opportunity with low P/S (0.4) and P/B (1.12) ratios, trading below the consensus price target of $102.00. Upside potential is supported by earnings beats and strategic investments in energy and autonomous driving, but risks include margin pressure, rising debt levels (46.79% debt-to-asset in 2024), and competitive auto market dynamics. Institutional sentiment remains bullish despite near-term headwinds.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
